Security
ARCT · Arcturus Therapeutics Holdings Inc.
ARCTNASDAQCommon stockCurrentCIK 1768224Updated Sep 27, 2026
ARCT price & chart
Loading TradingView…
NASDAQ:ARCT on TradingView ↗About the company
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory therapeutics with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus’ strategic collaborations include Thermo Fisher Scientific for ARCT-032 manufacturing and development, BARDA for pandemic influenza initiatives, and ARCALIS, a Japanese joint venture focused on manufacturing mRNA vaccines and therapeutics. Arcturus’ pipeline includes programs in cystic fibrosis (CF), ornithine transcarbamylase (OTC) deficiency, phenylketonuria (PKU) and Gout. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA (siRNA), circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive…
In the news
No coverage from other publishers is available.
Seeking Alpha
Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform - Slideshow ↗
Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform Transcript ↗
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Items 1.01, 7.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 271,148,000Source | 344,069,000Source | 429,402,000Source | 450,387,000Source |
| Property, Plant and Equipment, NetUSD | 6,736,000Source | 9,531,000Source | 12,427,000Source | 12,415,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 230,909,000Source | 237,028,000Source | 292,005,000Source | 391,883,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 5,564,000Source | 3,974,000Source | 32,064,000Source | 2,764,000Source |
| Assets, CurrentUSD | 241,446,000Source | 305,979,000Source | 386,590,000Source | 403,333,000Source |
| Operating Lease, Right-of-Use AssetUSD | 21,081,000Source | 26,674,000Source | 28,500,000Source | 32,545,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 57,163,000Source | 103,091,000Source | 150,889,000Source | 180,075,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 28,000Source | 27,000Source | 27,000Source | 27,000Source |
| Additional Paid in CapitalUSD | 728,547,000Source | 689,758,000Source | 646,352,000Source | 608,426,000Source |
| Retained Earnings (Accumulated Deficit)USD | -514,590,000Source | -448,807,000Source | -367,866,000Source | -338,141,000Source |
| Stockholders' Equity Attributable to ParentUSD | 213,985,000Source | 240,978,000Source | 278,513,000Source | 270,312,000Source |
| Liabilities and EquityUSD | 271,148,000Source | 344,069,000Source | 429,402,000Source | 450,387,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 36,379,000Source | 65,489,000Source | 81,989,000Source | 126,984,000Source |
| Operating Lease, Liability, CurrentUSD | 4,214,000Source | 3,552,000Source | 4,309,000Source | 3,884,000Source |
| Accounts Payable, CurrentUSD | 4,235,000Source | 7,194,000Source | 5,279,000Source | 7,449,000Source |
| Operating Lease, Liability, NoncurrentUSD | 20,784,000Source | 24,998,000Source | 25,907,000Source | 30,216,000Source |
| Other Liabilities, NoncurrentUSD | — | — | 497,000Source | 2,804,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 23,898,000Source | 38,781,000Source | 31,881,000Source | 30,232,000Source |
| Deferred Revenue, CurrentUSD | 8,246,000Source | 19,514,000Source | 44,829,000Source | 28,648,000Source |
| Deferred Revenue, NoncurrentUSD | — | 12,604,000Source | 42,496,000Source | 20,071,000Source |
| Long-term Debt, Current MaturitiesUSD | — | — | — | 60,655,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 25,408,000Source | 37,988,000Source | 34,649,000Source | 30,611,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 1,590,000Source | -28,090,000Source | 29,300,000Source | -603,000Source |
| Increase (Decrease) in Accounts PayableUSD | -2,959,000Source | 1,915,000Source | -2,238,000Source | -3,112,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -74,271,000Source | -59,747,000Source | -18,099,000Source | 31,993,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -230,000Source | -648,000Source | -2,901,000Source | -7,726,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 230,000Source | 648,000Source | 2,901,000Source | 7,726,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 13,382,000Source | 5,418,000Source | -24,087,000Source | -2,859,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -61,119,000Source | -54,977,000Source | -45,087,000Source | 21,408,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 232,794,000Source | 293,913,000Source | 348,890,000Source | 393,977,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | 2,127,000Source | 813,000Source |
| Income Taxes Paid, NetUSD | — | 1,407,000Source | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 25,408,000Source | 37,988,000Source | 34,649,000Source | 30,611Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 382,000Source | -471,000Source | -229,000Source | -598,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | -382,000Source | -471,000Source | -90,000Source | -375,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | 33,953,000Source | — |
| General and Administrative ExpenseUSD | 46,079,000Source | 52,823,000Source | 52,871,000Source | 46,071,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | -515,000Source |
| Income Tax Expense (Benefit)USD | — | -4,000Source | 1,835,000Source | 1,295,000Source |
| Net Income (Loss) Attributable to ParentUSD | -65,783,000Source | -80,941,000Source | -29,725,000Source | 9,349,000Source |
| Operating ExpensesUSD | 158,291,000Source | 247,979,000Source | 245,004,000Source | 193,822,000Source |
| Operating Lease, Impairment LossUSD | 1,897,000Source | — | — | — |
| Other Nonoperating Income (Expense)USD | 10,095,000Source | 15,195,000Source | 16,591,000Source | -420,000Source |
| Proceeds from Issuance of Common StockUSD | 11,688,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | 1,109,000Source | 4,736,000Source | 2,668,000Source | 1,730,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 82,031,000Source | 152,310,000Source | 166,799,000Source | 205,999,000Source |
| Operating Income (Loss)USD | -76,260,000Source | -95,669,000Source | -78,205,000Source | 12,177,000Source |
| Other Nonoperating Income (Expense)USD | 10,095,000Source | 15,195,000Source | 16,591,000Source | -420,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -65,783,000Source | -80,945,000Source | -27,890,000Source | 10,644,000Source |
| Income Tax Expense (Benefit)USD | — | -4,000Source | 1,835,000Source | 1,295,000Source |
| Net Income (Loss) Attributable to ParentUSD | -65,783,000Source | -80,941,000Source | -29,725,000Source | 9,349,000Source |
| Earnings Per Share, BasicUSD per share | -2.4Source | -3Source | -1.12Source | 0.35Source |
| Earnings Per Share, DilutedUSD per share | -2.4Source | -3Source | -1.12Source | 0.35Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 27,386,000Source | 27,000,000Source | 26,628,000Source | 26,445,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 27,386,000Source | 27,000,000Source | 26,628,000Source | 27,093,000Source |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | — | -4,000Source | 1,835,000Source | 1,295,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 3,025,000Source | 3,544,000Source | 2,957,000Source | 1,527,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 382,000Source | -471,000Source | -229,000Source | -598,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | -382,000Source | -471,000Source | -90,000Source | -375,000Source |
| General and Administrative ExpenseUSD | 46,079,000Source | 52,823,000Source | 52,871,000Source | 46,071,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -65,783,000Source | 81,050,000Source | -27,890,000Source | 10,644,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | -515,000Source |
| Operating ExpensesUSD | 158,291,000Source | 247,979,000Source | 245,004,000Source | 193,822,000Source |
| Research and Development ExpenseUSD | 112,212,000Source | 195,156,000Source | 192,133,000Source | 147,751,000Source |
Filing attachments
e665798_ex99-2.htm · 8-K · 2026-09-23
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform ARCT-810 generally safe and well tolerated, demonstrating encouraging activity across key urea cycle biomarkers in ongoing Phase 2 study LUNAR 2.0™ produces greater than 30-fold higher protein expression in multiple NHP studies - unlocks new therapeutic opportunities ARCT-2601, an OTC deficiency therapeutic candidate utilizing LUNAR 2.0™, to be integrated by …
Read attachment ↗e665679_ex99-1.htm · 8-K · 2026-08-06
EX-99.1 2 e665679_ex99-1.htm Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress ARCT-032 (CF) Phase 2 study enrollment remains on schedule; the decision to proceed into Phase 3 expected Q4 2026 ARCT-810 (OTC Deficiency) Phase 2 study enrollment and dosing completed; data and regulatory plan to be communicated Q3 2026 Arcturus regains global rights to KOSTAIVE® and infectious disease portfolio; receives $12 million in cash and $16 million in released…
Read attachment ↗e665618_ex99-1.htm · 8-K · 2026-07-02
EX-99.1 2 e665618_ex99-1.htm Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing rights SAN DIEGO, Calif. --(BUSINESS WIRE)--July 2, 2026--Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today ann…
Read attachment ↗e665435_ex99-1.htm · 8-K · 2026-05-07
EX-99.1 3 e665435_ex99-1.htm Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress Initiated enrollment (Q1 2026) earlier than expected for 12-week cystic fibrosis (CF) open label Phase 2 study; lung function (ppFEV1 and LCI) is being monitored in Class I CF subjects Received regulatory direction on pediatric development strategy from FDA (Type C meeting) for ornithine transcarbamylase (OTC) deficiency program; End of Phase 2 (EOP2) meeting H2 2026 Inve…
Read attachment ↗